← Back to Search

Other

AR-15512 Eye Drops for Dry Eye Syndrome

Phase 3
Recruiting
Research Sponsored by Alcon Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Within the last 6 months, have used, or desired to use artificial tears for dry eye symptoms
Within the last 12 months, have a previous history of dry eye disease, either clinician diagnosed or patient reported
Must not have
Current evidence of any clinically significant ophthalmic disease other than dry eye (for example, glaucoma or macular degeneration)
History of ocular surgery within 1 year of the Study Visit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, minute 0 (pre-instillation); day 1, minute 3 (post-instillation)
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial aims to see how well a new eye drop called AR-15512 0.003% can increase tear production in people with dry eye disease.

Who is the study for?
This trial is for individuals who have used or wanted to use artificial tears for dry eye symptoms in the last 6 months, have a vision score of 20/200 or better, and overall good eye health. They must not have worn contact lenses or used lid hygiene products within the past week, nor any ocular anti-inflammatory medications within the past month.
What is being tested?
The study tests how well a new ophthalmic solution called AR-15512 (0.003%) increases tear production in people with Dry Eye Disease (DED). Participants will receive an acute dose of this medication to assess its effectiveness.
What are the potential side effects?
While specific side effects are not listed here, potential side effects may include irritation at the site of application, redness, discomfort, or other reactions related to eye drops.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have used or wanted to use artificial tears for dry eyes in the last 6 months.
Select...
I have had dry eye disease in the past year.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any serious eye conditions besides dry eye.
Select...
I have not had eye surgery in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, minute 0 (pre-instillation); day 1, minute 3 (post-instillation)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, minute 0 (pre-instillation); day 1, minute 3 (post-instillation) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline (pre-drop compared to 3 minutes post-drop) in tear meniscus height (TMH) as measured by optical coherence tomography (OCT)

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 0.003% AR-15512Experimental Treatment1 Intervention
One drop in each eye in a staggered cadence (left eye followed by dosing of the right eye) approximately 2-4 hours apart

Find a Location

Who is running the clinical trial?

Alcon ResearchLead Sponsor
732 Previous Clinical Trials
128,779 Total Patients Enrolled
Clinical Trial Lead, PharmaStudy DirectorAlcon Research, LLC
3 Previous Clinical Trials
600 Total Patients Enrolled
~40 spots leftby Mar 2025